Wave Life Sciences, Inc. is a clinical-stage biotechnology company dedicated to unlocking the potential of RNA medicines to transform human health. The company's core technology is its proprietary PRISM platform, which combines chemistry innovation, multiple RNA-targeting modalities, and deep insights into human genetics to design and manufacture stereopure oligonucleotides. Wave's therapeutic pipeline spans several modalities, including RNA editing (AIMers), RNA interference (SpiNA), and exon skipping, allowing it to tailor its approach to specific disease biology.
The company's clinical pipeline features lead programs targeting both rare and high-prevalence diseases. Key programs include WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency (AATD), WVE-N531 for Duchenne muscular dystrophy (DMD), and WVE-003 for Huntington's disease. In 2024, Wave achieved a significant milestone by demonstrating the first-ever clinical RNA editing in humans with its WVE-006 program.
Wave Life Sciences operates primarily out of its headquarters in Cambridge, Massachusetts, and maintains a strategic collaboration with GSK to advance oligonucleotide therapeutics. Revenue is currently generated through collaboration agreements, milestone payments, and research funding rather than commercial product sales, as its candidates remain in the clinical and preclinical stages of development.
